U.S. Government Shutdown: Consequences for manufacturers and strategic mitigation measures

The ongoing 2025 U.S. government shutdown — one of the longest in recent history — has forced multiple federal agencies, including the Food & Drug Administration (FDA), to operate with limited resources. According to the FDA’s FY 2026 Lapse in Funding Information¹, only activities addressing imminent threats to human life or funded by carryover user fees continue during the lapse period. All other regulatory and administrative functions are paused until new appropriations are enacted.

For manufacturers of medical devices, this creates a complex environment requiring strategic anticipation and regulatory agility. Yet, history shows that businesses able to keep projects moving and finances steady during these pauses come out stronger once normal operations resume. The below article analyzes shutdown impacts and proposes concrete steps to ensure continuity of operations and limit financial burden.

¹The FDA’s Fiscal Year 2026 Lapse in Funding Information, is the FDA’s contingency-planning webpage (or PDF factsheet) that is published whenever there is a possibility that Congress will not enact an appropriation (or a continuing resolution) at the start of the fiscal year—in this case, FY 2026, which begins 1 October 2025.

1. Consequences for medical devices manufacturers

The shutdown can have far-reaching consequences for medical device manufacturers both within and without the US. While a prolonged shutdown will not force manufacturers to conduct major technical rework, however, prolonged delays can disrupt regulatory planning, internal project sequencing, and contractual timelines with partners or investors.

Firms should monitor FDA guidance updates and ensure submission readiness for when the agency reopens.

1.1. Frozen submissions

Manufacturers that did not submit their 510(k), De Novo, or PMA (Pre-Market Authorization) before October 1, 2025, are unable to move forward with the marketing clearance/authorization of their products in the US.
Since the FDA does not have legal authority to accept new user-fee payments during the lapse period, submissions requiring such payment cannot be accepted, even if the application itself is ready for review.

This affects:

• Startups preparing their first FDA submission.
• Small- and mid-sized U.S. firms seeking to launch next-generation products.
• International manufacturers planning market entry.

There is no preferential treatment for domestic companies — all are equally subject to the shutdown’s restrictions. As a result, months of regulatory preparation may be stalled indefinitely, and project schedules tied to regulatory milestones may be disrupted.

1.2. Registration risk

Every registered establishment must renew its FDA registration annually between October 1 and December 31. Establishments that fail to complete renewal by the deadline are considered unregistered as of January 1 and may not legally market or import devices in the U.S. until registration is restored.

During the shutdown, however, the FDA’s registration and listing systems are inaccessible, and user fees cannot be paid. As a result, current registrations remain valid only until December 31, 2025 and companies unable to renew by that date may face temporary loss of market authorization in January2026. Importers could experience shipment holds or customs delays, as products will appear unregistered in the FDA’s systems.

While the FDA has not announced any official extensions to registration deadlines, in previous shutdowns the agency resumed processing renewals without penalizing firms affected by system inaccessibility. Companies are therefore encouraged to retain documentation of renewal or payment attempts made during the lapse period.

For non-U.S. manufacturers, the U.S. Agent serves as the official FDA point of contact and often assists with registration updates or submissions to the FDA system. While not legally responsible for managing renewals, the agent frequently performs this task on behalf of the manufacturer under a separate service agreement.

Consequently, for non-U.S. manufacturers relying on U.S. Agents to manage renewals, this creates a communication bottleneck and legal uncertainty. Some companies are already preparing contingency documentation (e.g., proof of payment attempts, internal correspondence) to demonstrate intent to comply once systems reopen.
Once FDA operations resume, review and processing timelines may temporarily lengthen as the agency works to clear accumulated backlogs and reallocate resources. This reinforces the importance of maintaining regulatory resilience and readiness during periods of administrative disruption.

1.3. Loss of revenue and market delay

For start-ups and small manufacturers, time is a critical economic resource. Each month of delay in obtaining FDA clearance can:

• Postpone commercial launch and sales revenue,
• Delay investor milestones,
• Extend cash burn rates, and
• Reduce competitive advantage in fast-moving technology sectors (AI, wearables, minimally invasive devices, etc.).

In some cases, investors condition additional funding on receiving FDA clearance or Investigational Device Exemption (IDE) approval. Therefore, regulatory paralysis can quickly evolve into financial instability for early-stage firms. For instance, a small company expecting clearance by Q4 2025 may now be forced to shift launch plans into mid-2026, affecting contracts, marketing campaigns, and even workforce planning.

Large corporations may absorb such delays more easily, but small and mid-sized innovators often depend on continuous regulatory progress to sustain valuation and investor confidence.

1.4. Increased stress on global supply chains

The FDA’s responsibilities extend beyond device approval — they include import regulation and customs control for medical products. During a shutdown, fewer inspectors are available to manage imports, slowing documentation review significantly. Some products may face temporary holds until verification can occur.

This impacts international manufacturers shipping devices, components, or sterile materials into the U.S. in various ways.Even if their registrations remain technically valid, slower verification at customs creates delays, increases demurrage fees, and may generate potential shortages downstream. As a result, hospitals and distributors could see inventory fluctuations, particularly for specialized devices with limited suppliers, thus inflating procurement costs and potentially disrupting patient care.

Moreover, delays in customs release may affect clinical trials dependent on imported investigational devices, leading to forced enrollment pauses, rescheduled patient procedures, data gaps as well as protocol deviations that can jeopardize statistical power. In the most serious cases, prolonged shortages can even invalidate portions of the study, requiring costly redesign or repetition.

1.5. Long-term repercussions

Beyond immediate disruptions, shutdowns erode predictability — a core element of regulatory planning.Manufacturers may need to reassess launch strategies based on political cycles, diversify market approvals (CE (European Union), MHRA (United Kingdom), PMDA (Japan)) to mitigate single-market dependency, and implement risk buffers into regulatory timelines.

Each shutdown reinforces the need for regulatory resilience — the capacity to maintain compliance readiness, financial flexibility, and documentation integrity despite unpredictable political conditions.

2. Strategic mitigation measures

While the 2025 U.S. government shutdown remains beyond the control of manufacturers, its impact can be strategically mitigated through proactive planning, diversification, and disciplined regulatory readiness.
The following measures are recommended for medical device companies seeking to reduce operational and financial exposure.

• Maintain Submission Readiness and Pre-Submission Engagement: Continue preparing all technical documentation, testing data, and labeling materials to ensure immediate submission once FDA operations resume.
  Use the FDA’s Pre-Submission (Q-Sub) program — which remains open — to obtain preliminary feedback on study designs, risk classifications, or device modifications.
  This approach shortens time to market once submissions are accepted again.

• Apply or Renew Small Business Certification: Companies eligible for small business status (annual revenues under USD 100 million) should submit their certification request now. The process is still operational and typically requires 60 days.
  Having certification in place ensures that manufacturers can benefit from reduced user fees immediately when submission processing restarts, avoiding costly delays.

• Strengthen Quality Systems and Production Controls: Downtime should be leveraged to enhance process validation, supplier oversight, and CAPA effectiveness.
  Historical data show that the majority of recalls stem from manufacturing process control failures, not design flaws. By tightening internal systems now, companies reduce post-market risk once products reach the market.

• Preserve Market Access Through Communication and Documentation: Maintain transparent communication with U.S. Agents, distributors, and regulatory partners.
  If registration renewal cannot be completed, retain documentation demonstrating your intent to comply (payment attempts, emails, screenshots). Such evidence may assist in demonstrating good faith to the FDA or customs authorities after reactivation.

• Diversify Regulatory and Commercial Strategies: To mitigate overreliance on the U.S. market, pursue parallel CE Marking, MHRA, or PMDA submissions when possible.
  Although not equivalent to FDA clearance, these markets can provide business continuity and investor confidence during U.S. regulatory interruptions.
  In addition, consider targeting regions with stable review processes to maintain global revenue flow.

• Strengthen Financial and Project Risk Management: Reassess financial projections and adjust cash flow models to account for regulatory delays of at least 60–90 days.
  Communicate proactively with investors or boards about contingency measures.
  Integrating shutdown-related risk into financial planning reinforces corporate resilience and credibility.

Manufacturers that leverage regulatory downtime to strengthen compliance systems and documentation are best positioned to resume operations efficiently when normal FDA activity resumes.

3. Conclusion

The 2025 U.S. government shutdown underscores the importance of maintaining regulatory agility and business continuity planning. Medical device manufacturers that anticipate operational disruptions, strengthen internal systems, and diversify their market strategy can mitigate both short-term and structural risks. In practice, this means building redundancies into supply chains, cultivating proactive dialogue with regulators and partners, and securing alternative financing or clinical pathways in non-U.S. jurisdictions. Embedding these safeguards into everyday operations not only helps firms ride out a shutdown but also positions them for greater resilience and global competitiveness once normal conditions resume

Need help?

Efor’s regulatory experts support manufacturers in navigating FDA submissions, quality system optimization, and market access challenges.

For guidance on sustaining regulatory readiness and strategic compliance planning in uncertain contexts, contact Efor U.S. at solutionprojectdelivery@efor-group.com.